Bridging the gap: The endocannabinoid system as a functional fulcrum for benzodiazepines in a novel frontier of anxiety pharmacotherapy.

While benzodiazepines have been a mainstay of the pharmacotherapy of anxiety disorders, their short-term efficacy and risk of abuse have driven the exploration of alternative treatment approaches. The endocannabinoid (eCB) system has emerged as a key modulator of anxiety-related processes, with evidence suggesting dynamic interactions between the eCB system and the GABAergic system, the primary target of benzodiazepines. According to the existing literature, the activation of the cannabinoid receptors has been shown to exert anxiolytic effects, while their blockade or genetic deletion results in heightened anxiety-like responses.

Diagnostic performance of artificial intelligence in multiple sclerosis: a systematic review and meta-analysis.

Background: The expansion of the availability of advanced imaging methods needs more time, expertise, and resources which is in contrast to the primary goal of the imaging techniques. To overcome most of these difficulties, artificial intelligence (AI) can be used. A number of studies used AI models for multiple sclerosis (MS) diagnosis and reported diverse results.

Rapid treatments for depression: Endocannabinoid system as a therapeutic target.

Current first-line treatments for major depressive disorder (MDD), i.e., antidepressant drugs and psychotherapy, show delayed onset of therapeutic effect as late as 2-3 weeks or more.

Artificial intelligence in the diagnosis of multiple sclerosis: A systematic review.

Background: In recent years Artificial intelligence (AI) techniques are rapidly evolving into clinical practices such as diagnosis and prognosis processes, assess treatment effectiveness, and monitoring of diseases. The previous studies showed interesting results regarding the diagnostic efficiency of AI methods in differentiating Multiple sclerosis (MS) patients from healthy controls or other demyelinating diseases. There is a great lack of a comprehensive systematic review study on the role of AI in the diagnosis of MS.

Statins and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis.

Amyotrophic lateral sclerosis (ALS) is a paralytic, heterogeneous and progressive disease characterized by the degeneration of both upper and lower motor neurons. Several studies about the effects of statins drug on the risk of ALS showed contradictory results and evidence for this is inconclusive. So we aimed to perform a meta-analysis on previous studies to clarify the association between statin use and risk of ALS.